Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

New Technique Uses ‘Simulated’ Human Heart to Screen Drugs

July 21, 2014 By Coventry University

A Coventry University scientist has developed a pioneering new way – using samples of beating heart tissue – to test the effect of drugs on the heart without using human or animal trials.

The breakthrough is the work of Dr. Helen Maddock – an expert in cardiovascular physiology and pharmacology from the University’s Centre for Applied Biological and Exercise Sciences – and could lead to the lives of hundreds of future patients being saved and the quality of their treatments improved.

Adverse effects of drugs on the cardiovascular system are a major cause of many medical treatments failing, but heart-related side-effects can often only be detected once a drug is being used on patients in clinical trials – by which time it is too late.

Dr. Maddock’s ‘in vitro’ technique – which means ‘in glass’ in reference to it taking place in a laboratory environment rather than in a living organism – uses a specimen of human heart tissue attached to a rig allowing the muscle to be lengthened and shortened whilst being stimulated by an electrical impulse, mimicking the biomechanical performance of cardiac muscle.

Trial drugs can then be added to the tissue to determine whether or not they have an adverse effect on the force of contraction of the muscle (and therefore of the heart), a test that could only previously be performed ‘in vivo’ – i.e. on living animals – often with inconclusive results.

This ‘simulated’ cardiovascular system – known as a work-loop assay – provides the most realistic model of heart muscle dynamics in the world to date, and opens up unprecedented possibilities for identifying negative effects of drugs early and inexpensively – potentially saving lives and speeding up the development of successful drug treatments.

Dr. Maddock has formed a spin-out company – InoCardia Ltd – from Coventry University to begin implementing her groundbreaking technique in the pharma industry, and it has already received a quarter of a million pound investment from Warwickshire-based technology investment firm Mercia Fund Management.

Dr. Maddock, who spent almost ten years developing the technique, said, “I’m delighted that our research is at a stage where we can confidently say the work-loop assay we’ve created is the world’s only clinically relevant in vitro human model of cardiac contractility. It has the potential to shave years off the development of successful drugs for a range of treatments.”

“Both the pharma industry and regulators recognise that existing methods of assessing the contractility of the heart are fraught with problems, so we’re incredibly excited to be able to introduce a new way to accurately determine the safety of drugs in respect of the heart without the need to test on humans or animals.”

Mark Payton, managing director of Mercia Fund Management, added, “InoCardia benefits from a proprietary approach following many years of investigation by Helen and her team, and offers the potential for early screening of compounds in development without the initial need for extensive animal trials. Through a markedly accelerated drug development process, this will decrease timelines to drug development, and as a consequence greatly reduce the cost of new drug development. The end beneficiary will, of course, be patients receiving novel treatments sooner.”

Dr. Maddock and InoCardia Ltd are already in discussions with a multinational biopharmaceutical company with a view to applying the assay in industry.

Related Articles Read More >

An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
How Abbott developed the first-of-its-kind Infinity DBS system
Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
Q&A with Darshin Patel, who led the Edwards Lifesciences Sapien M3 TMVR system’s development
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe